Standard Indications to Treat CLLAccording to international guidelines (iwCLL), treatment is indicated for patients who show any of the following signs of active disease:Progressive Bone Marrow Failure: Development of or worsening anemia (hemoglobin <10 g/dL) or thrombocytopenia (platelet count <100 × 10⁹/L).Autoimmune Complications: Autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP) that responds poorly to standard corticosteroid therapy.Massive or Symptomatic Organs: Progressive or bulky lymphadenopathy (lymph nodes greater than 10 cm in longest dimension) or splenomegaly (spleen extending more than 6 cm below the costal margin).Progressive Lymphocytosis: A rapid rise in lymphocyte count (such as an increase of more than 50% over a 2-month period or a lymphocyte doubling time of less than 6 months), only if accompanied by other active features.Constitutional Symptoms: Unintentional weight loss of 10% or more within the previous 6 months, significant fatigue (ECOG performance status 2 or worse), fevers above 38°C for 2 or more weeks without evidence of infection, or severe drenching night sweats lasting over a month.Advanced Clinical Stage: Disease progression to Rai stage III/IV or Binet st
Standard Indications to Treat CLLAccording to international guidelines (iwCLL), treatment is indicated for patients who show any of the following signs of active disease:Progressive Bone Marrow Failure: Development of or worsening anemia (hemoglobin <10 g/dL) or thrombocytopenia (platelet count <100 × 10⁹/L).Autoimmune Complications: Autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP) that responds poorly to standard corticosteroid therapy.Massive or Symptomatic Organs: Progressive or bulky lymphadenopathy (lymph nodes greater than 10 cm in longest dimension) or splenomegaly (spleen extending more than 6 cm below the costal margin).Progressive Lymphocytosis: A rapid rise in lymphocyte count (such as an increase of more than 50% over a 2-month period or a lymphocyte doubling time of less than 6 months), only if accompanied by other active features.Constitutional Symptoms: Unintentional weight loss of 10% or more within the previous 6 months, significant fatigue (ECOG performance status 2 or worse), fevers above 38°C for 2 or more weeks without evidence of infection, or severe drenching night sweats lasting over a month.Advanced Clinical Stage: Disease progression to Rai stage III/IV or Binet st
Created using ChatSlide
This guide outlines the critical steps for initiating treatment for Chronic Lymphocytic Leukaemia (CLL). It emphasises the use of iwCLL criteria to identify active disease, prioritising cases with progressive marrow failure, and confirming advanced stages. Recognising high-risk features such as bulky nodes and splenomegaly is essential, alongside monitoring lymphocyte levels and treating steroid-refractory conditions. Finally, it stresses the importance of systematic assessment of symptoms...